Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
Timothy Juday,1 Todd Correll,1 Ayanna Anene,2 Michael S Broder,2 Jesse Ortendahl,2 Tanya Bentley21Bristol-Myers Squibb, Plainsboro, NJ, USA; 2Partnership for Health Analytic Research LLC, Beverly Hills, CA, USABackground: February 2013 US treatment guidelines recommend the once-daily tablet of efavi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-09-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Online Access: | http://www.dovepress.com/cost-effectiveness-of-the-once-daily-efavirenzemtricitabinetenofovir-t-a14238 |